What a split-sample exercise can establish, and what it cannot
Two years ago we ran an anonymised version of this comparison and promised a named one. This is it, with every method printed in full.
The Ledger in 2024
Page 2 of 11 of this archive, newest first.
Saudi Arabia caps dulaglutide prescribing to 9 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
Blind duplicates: what happens when a laboratory does not know it is being watched
Two years ago we ran an anonymised version of this comparison and promised a named one. This is it, with every method printed in full.
Why a result on one vial says less than the trade needs it to
A result on one vial generalises to a batch only if the vial was drawn in a way that makes it representative — and nobody records how it was drawn.
South Korea declines to reimburse tirzepatide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
The shortage years, and what they taught about interruption
Real-world persistence figures, with their definitions stated, because the definitions are doing most of the work.
Switzerland caps semaglutide prescribing to 8 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
Japan declines to reimburse exenatide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
Australia declines to reimburse semaglutide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
Turkey caps liraglutide prescribing to 12 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
Reproducibility, measured rather than assumed
The Journal submitted split samples from single lots to three assay services, under names unconnected to this publication, and published each method alongside each result.
India caps liraglutide prescribing to 17 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
Why people actually stop, in the order they actually stop
A supply interruption is a discontinuation with no notice, no taper and no plan. That is a distinct clinical situation.
Sweden caps tirzepatide prescribing to 16 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
Sweden declines to reimburse liraglutide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
Argentina caps exenatide prescribing to 16 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
India declines to reimburse dulaglutide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
Nigeria caps tirzepatide prescribing to 6 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
Brazil declines to reimburse dulaglutide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
Side effects, cost, supply, target: four reasons with four trajectories
Cost is the modal reason for discontinuation in every dataset we have seen, and it is absent from the clinical literature.